Retrospective Study Published in Pharmacotherapy Identifies Advanced Age, Obesity, Pre-Surgery Opioid Use and Comorbid Conditions as Predictive Risk Factors for Adverse Events
Press Release: Pacira Pharmaceuticals, Inc. – 3 hours ago
PARSIPPANY, N.J.--(BUSINESS WIRE)--
Pacira Pharmaceuticals, Inc. (PCRX) today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital healthcare system and received opioids for postsurgical pain management. According to the data, published in this month’s issue of Pharmacotherapy, patients who experienced opioid-related adverse events (ORAEs) had statistically significantly higher hospital costs, longer hospital stays and increased risks of readmission and mortality.
Specifically, patients experiencing an ORAE:
Had a 55 percent longer hospital stay than patients without an ORAE (9.5 days vs. 6.1 days, P
Had a 47 percent higher hospitalization cost compared to patients without an ORAE ($21,012 vs. $14,291, P
Had a 36 percent increased risk of 30-day readmission compared to patients without an ORAE (P
Had a 3.4 times greater risk of inpatient mortality than patients without an ORAE (P
Researchers were also able to identify a series of characteristics that increased patients’ risks for ORAEs. Predictive risk factors for an adverse event related to opioid use included: patient age of 65 or older, obesity, greater number of comorbidities and pre-surgery opioid use.
“This regionally focused analysis mirrors findings from previously published national analyses that demonstrated the meaningful and measurable impact of opioid-related adverse events on patient outcomes and healthcare system costs,” said Dave Stack, President and CEO of Pacira Pharmaceuticals, Inc. “While opioids have long been the mainstay of postsurgical pain management, a recent groundswell of advocacy to mitigate potentially fatal side effects may drive a shift in the current postsurgical pain management paradigm toward non-opioid or opioid-sparing pain regimens, especially in high-risk patients.”
In this retrospective analysis, researchers reviewed administrative discharge data at 26 hospitals in the southeastern United States, and identified 37,031 adult patients who underwent common soft tissue and orthopedic surgical procedures from January 2009 to December 2010. Among this patient sample, 98.6 percent received opioids after surgery, and 13.6 percent of those received a diagnosis of respiratory, gastrointestinal, central nervous system, urinary or other opioid-related adverse events during hospitalization.
Researchers conducted statistical analysis to evaluate risk factors that may predispose patients to postsurgical ORAEs and compared differences in length of stay, total hospitalization costs, 30-day readmission rates and inpatient mortality between the patients who experienced an ORAE and those who did not.
The research was supported by Pacira Pharmaceuticals, Inc. The full publication is available online here.
Recent PCRX News
- Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 • GlobeNewswire Inc. • 05/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:13:45 PM
- Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes • GlobeNewswire Inc. • 05/08/2024 08:05:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:01:03 PM
- Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program • GlobeNewswire Inc. • 05/07/2024 08:00:00 PM
- Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024 • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 12:00:00 PM
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee • GlobeNewswire Inc. • 03/13/2024 11:00:00 AM
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 08:33:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:03:32 PM
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Pacira to Report 2023 Financial Results on Thursday February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy • GlobeNewswire Inc. • 02/15/2024 01:36:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:59:39 PM
- Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc. • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams • PR Newswire (US) • 02/01/2024 03:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:25:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:24:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:21:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:18:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:02:42 PM
- Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues • GlobeNewswire Inc. • 01/04/2024 10:00:41 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM